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and transcriptomes of primary intestinal epithelial cells (IEC) of
children newly diagnosed with inﬂammatory bowel diseases
(IBD) to learn more about pathogenesis. METHODS: We ob-
tained mucosal biopsies (n ¼ 236) collected from terminal
ileum and ascending and sigmoid colons of children (median
age, 13 years) newly diagnosed with IBD (43 with Crohn’s
disease [CD], 23 with ulcerative colitis), and 30 children
without IBD (controls). Patients were recruited and managed at
a hospital in the United Kingdom from 2013 through 2016. We
also obtained biopsies collected at later stages from a subset of
patients. IECs were puriﬁed and analyzed for genome-wide
DNA methylation patterns and gene expression proﬁles.
Adjacent microbiota were isolated from biopsies and analyzed
by 16S gene sequencing. We generated intestinal organoid
cultures from a subset of samples and genome-wide DNA
methylation analysis was performed. RESULTS: We found gut
segment-speciﬁc differences in DNA methylation andFLA 5.5.0 DTD  YGAST61474_prooftranscription proﬁles of IECs from children with IBD vs con-
trols; some were independent of mucosal inﬂammation.
Changes in gut microbiota between IBD and control groups
were not as large and were difﬁcult to assess because of large
amounts of intra-individual variation. Only IECs from patients
with CD had changes in DNA methylation and transcription
patterns in terminal ileum epithelium, compared with controls.
Colon epithelium from patients with CD and from patients with
ulcerative colitis had distinct changes in DNA methylation and
transcription patterns, compared with controls. In IECs from
patients with IBD, changes in DNA methylation, compared with
controls, were stable over time and were partially retained in
ex-vivo organoid cultures. Statistical analyses of epithelial cell
proﬁles allowed us to distinguish children with CD or ulcerative
colitis from controls; proﬁles correlated with disease outcome
parameters, such as the requirement for treatment with bio-
logic agents. CONCLUSIONS: We identiﬁed speciﬁc changes in




The intestinal epithelium is thought to play a critical role in
the pathogenesis of inﬂammatory bowel Diseases (IBD),
yet evidence derived from primary human tissue remain
scarce.
NEW FINDINGS
Puriﬁed intestinal epithelium from children newly
diagnosed with IBD display distinct epigenetic and
transcriptional alternations, which are partly retained in
organoid cultures and correlate with disease outcome.
LIMITATIONS
Relatively small patient numbers require validation in
additional cohorts.
IMPACT
Stable epigenetic alterations in the intestinal epithelium of
children with IBD may explain variations in disease
outcome and have potential to be developed into
disease prognostic biomarkers in the future.




























































































ATpediatric patients with IBD compared with controls. These data
indicate that IECs undergo changes during IBD development
and could be involved in pathogenesis. Further analyses of
primary IECs from patients with IBD could improve our
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239Ilapsing inﬂammation that can affect any segments of
the digestive tract (ie, Crohn’s disease [CD]) or be restricted
to the colon (ulcerative colitis [UC]).1,2 Although these dis-
eases can manifest at any age, approximately one quarter of
patients3 are diagnosed in childhood or early adulthood,
when the disease course and subsequent outcomes can be
particularly severe.3
The etiology of IBD is multifactorial, although the
interplay of factors is still poorly understood. Large-scale
genome-wide association studies have helped to charac-
terize the genetic risk, identifying over 200 disease-
associated loci.4,5 The striking overlap of genetic risk loci
between CD, UC, and other immune-mediated diseases
strongly suggests common immune regulatory pathways are
affected in these conditions.4,5 However, current estimates
of the overall genetic contribution to IBD risk are still only
13% for CD and 8% for UC. The rapid increase in the inci-
dence of IBD in recent decades,6–8 the stability of the human
genome, the dysbiosis of the gut microbiome,9–12 as well as
epidemiologic evidence, all suggest an association between
the rise in IBD and the recent changes in our environment.
Epigenetic mechanisms operate at the interface between
genetic predisposition and our environment, capable of
causing stable, potentially heritable changes of cellularFLA 5.5.0 DTD  YGAST61474_prooffunction in response to environmental triggers.13,14 Conse-
quently, epigenetics is being increasingly recognized as a
highly plausible mechanism that may both initiate and then
maintain intestinal mucosal inﬂammation in human IBD. A
growing number of studies have reported IBD-associated
alterations in epigenetic proﬁles, as well as associated
changes in gene expression and/or cellular function. For
example, DNA methylation (DNAm) changes in mucosal bi-
opsies and peripheral blood mononuclear cells of both
adults and children diagnosed with IBD have been demon-
strated.15,16 However, the vast majority of studies were
performed on mixed cell tissue samples (eg, whole blood,
peripheral blood mononuclear cells Q, or mucosal biopsies)
and, possibly because of changes in cellular composition,
demonstrated a strong effect of inﬂammation on the
observed epigenetic changes. Importantly, advances made
by epigenetic consortia such as ROADMAP,17 BLUEPRINT,18
as well as single-cell RNA sequencing, have all demonstrated
the importance of studying individual, disease-relevant cell
types to best identify molecular alterations involved in
pathophysiology.
Genetic and functional studies predominantly using
mouse models and cell lines19–21 have provided strong
evidence for impaired function of the intestinal epithelium in
IBD. Yet, these models have done little to explain how the
complex interplay between environmental factors, host
genetics, intestinal cell function, and the adjacent micro-
biome lead to the development of the IBD phenotype and its
subsequent evolution. To better elucidate speciﬁc alterations
in this jigsaw, a genome-wide multi-layered omics approach
of carefully selected primary cell samples is required.
Importantly, in addition to unravelling novel aspects of dis-
ease pathogenesis, this approach in disease-relevant cell
types (ie, the intestinal epithelium) could provide clinically
relevant information. For example, in children and adults
with IBD, it can be difﬁcult to conﬁdently distinguish CD from
UC, with many patients remaining ‘unclassiﬁed’ despite dis-
ease progression. Intestinal epithelial cell (IEC)-speciﬁc
‘omics’ signatures have the potential to more rapidly and
accurately diagnose the patient and, hence, improve the
speciﬁcity of treatment management. Furthermore, varia-
tions of cell type-speciﬁc molecular proﬁles amongst IBD
patients may be indicative of disease sub-phenotype and
could therefore help to understand the large variations in













































































































































ATTherefore, we simultaneously proﬁled genotype, epi-
genotype (ie, DNAm), gene expression, and the adjacent gut
microbiome of highly puriﬁed IEC, obtained from children
newly diagnosed with IBD and a matched cohort of non-IBD
controls. We analyzed genome-wide ‘omics’ layers for po-
tential IBD-speciﬁc alterations and functional consequences,
as well as cross-talk between layers. Additionally, we gener-
ated intestinal epithelial organoids from patient biopsy
samples and investigated their epigenetic proﬁles. Lastly, we
applied statistical models to genome-wide datasets to test
their ability to distinguish between disease subtypes, as well
as potential correlation with disease outcome measures.
Methods
Patient Cohort
A cohort of 66 treatment-naïve children at diagnosis of their
IBD, along with 30 age- and sex-matched non-inﬂammatory
control children, were recruited by the Paediatric Gastroen-
terology team at Addenbrooke’s Hospital during 2013–2016.
This study was conducted with informed patient and/or carer
consent as appropriate, and with full ethical approval (REC-12/
EE/0482). Sample and patient details are provided in
Supplementary Tables 1 and 2. Children with macroscopically
and histologically normal mucosa who had a diagnosis of IBD
ruled out served as the non-disease control group. Each pa-
tient’s ﬁnal clinical diagnosis was based on the revised Porto
criteria.22 At the diagnostic colonoscopy, additional mucosal
biopsies were taken from the small bowel (ie, terminal ileum
[TI]) and 2 large bowel sections (ie, ascending colon [AC] and
sigmoid colon [SC]). A blood sample was taken for patient
genotyping. Clinical phenotype and outcome data were pro-
spectively recorded over a minimum of 18 months post-
diagnosis (Supplementary Table 1). The inﬂammation status
of a sample (inﬂamed vs non-inﬂamed) was based on the his-
tology of a paired sample taken within 2 cm of samples at the
time of the initial endoscopy. Longitudinal samples were taken
from the TI and SC of a subset of patients that underwent
repeat endoscopy (CD: n ¼ 14; UC: n ¼ 9).
Puriﬁcation of Intestinal Epithelium
Biopsy samples were processed immediately and IECs pu-
riﬁed using enzyme digestion and magnetic bead sorting for the
epithelial cell adhesion molecule as described previously.16,23
Mucus for the isolation of adjacent microbiota was collected
during tissue processing from sieve and centrifugation super-
natant, then pooled, pelleted, and stored at -80

C to extract
DNA from the adjacent microbiota. Further information is
provided in the supplementary materials.
Human Intestinal Epithelial Organoid Culture
Intestinal organoids were generated from mucosal biopsies
by isolation of intestinal crypts and culturing as described
previously and detailed in the Supplementary Methods section
and Supplementary Table 4.24
DNA and RNA Extraction
DNA and RNA were extracted simultaneously from the
same sample using the AllPrep DNA/RNA mini kit (Qiagen).FLA 5.5.0 DTD  YGAST61474_proofDNA from the adjacent microbiota was extracted using QIAamp
DNA Stool Mini Kit and from whole blood using the DNeasy
Blood and Tissue Kit (both Qiagen). DNA was bisulﬁte-
converted using Zymo DNA methylation Gold kit (Zymo
Research Q).
Arrays and Sequencing
Genome-wide DNA methylation was proﬁled using the
Illumina Inﬁnium HumanMethylation450 and EPIC BeadChip
platforms (Illumina, Cambridge, UK; Accession Numbers:
E-MTAB-5463). Sample numbers are provided in Supplementary
Table S3. Expression proﬁling was performed using RNA-
sequencing (RNA-seq) at the University of Kiel, Germany using
an established pipeline as described previously.10 (Project
accession number: E-MTAB-5464). Patient genotyping was
performed using the Illumina OmniExpressExome-8 BeadChip
Kit. 16S rRNA gene proﬁling of the adjacent microbiota was
performed at the Wellcome Trust Sanger Centre (Hinxton,
Cambridge). The 16S microbiota data can be found under EBI
study ID PRJEB6663. For further details of the arrays and
sequencing, please see the Supplementary Methods.
Locus-speciﬁc validation of DNA methylation proﬁles was
performed on bisulﬁte-converted DNA after polymerase chain
reaction Qampliﬁcation using the Pyromark Q24 (Qiagen) pyro-
sequencing system as described previously.16
Bioinformatics Analyses
Extensive details of the bioinformatics methods used in this
publication are described and referenced in the Supplementary
Methods. Brieﬂy, DNAm analyses were performed using
minﬁ,25 sva,26 DMRcate,27 and limma28 R packages. RNAseq
data was processed using established workﬂows.10 Microbiota
composition analysis was performed using QIIME and phylo-
seq.29 Differential analysis was performed using limma28 for
DNAm data (false discovery rate [FDR] <0.01) and DESeq230
for gene expression data (FDR <0.01 and log fold change
>± Q0.5). InnateDB31 and the Reactome pathways were used to
perform pathway enrichment analysis for the disease signa-
tures identiﬁed from omics data layers. The diagnostic potential
of omics data layers was tested using random forest classiﬁ-
cation models. Diagnostic accuracy was assessed via area under
the concentration-time curve (AUC Q), precision scores, and
receiver operator characteristic (ROC) curves. Weighted Gene
Co-expression Network Analysis (WGCNA)32 was applied to
gene expression and DNAm data for each diagnosis (CD and
UC) by gut segment to correlate omics datasets with clinical
phenotypic variables.Results
DNA Methylation and Gene Expression Proﬁling
of Puriﬁed Intestinal Epithelium Reveals Gut
Segment-speciﬁc and Disease-associated
Alterations
To investigate IEC pathophysiology in pediatric IBD, we
ﬁrst performed unsupervised analysis of genome-wide
DNAm, gene expression, and 16S microbial proﬁles gener-
ated from a total of 170 samples (Figure 1A and Table 1).
















Figure 1.Overview of study design and multi-dimensional scaling (MDS) analysis of genome-wide datasets. (A) Outline of
study design. (B) MDS plots for each dataset: (i) DNAm based on batch corrected M-values; (ii) r-log normalized RNAseq gene
expression counts; (iii) gut microbiota 16S operational taxonomic units normalized counts. Samples are labelled according to
diagnosis (CD, Crohn’s disease; UC, ulcerative colitis; control) and gut segment. Schematic in part A adapted from
Tauschmann et al.41


























































































































ATsimilarity/differences based on all data points included.
MDS plots of DNAm and gene expression proﬁles revealed
distinct clustering of samples by gut segment separating allFLA 5.5.0 DTD  YGAST61474_proofTI-derived epithelium from colonic (ie, AC and SC) samples
(Figure 1Bi and 1Bii). Moreover, samples derived from
controls clustered closely both on an epigenetic (DNAm) 8 January 2018  1:08 pm  ce
479
480
Table 1.Summary of Patients, Samples, and Generated Datasets
DNAm RNAseq 16S sequencing
GenotypeTI AC SC TI AC SC TI AC SC
Total samples at diagnosis 162 81 170 62
Total individuals 73 15 74 33 15 33 58 53 59 62
CD 31 5 32 11 5 11 21 21 22 24
450K cohort 13 5 13
EPIC cohort 17 18
Organoids 5 5
UC 18 5 18 11 5 11 18 16 18 18
450K cohort 13 5 13
EPIC cohort 5 5
Controls 24 5 24 11 5 11 19 16 19 20
450K cohort 14 5 14





AC, ascending colon; CD, Crohn’s disease; SC, sigmoid colon; TI, terminal ileum; UC ulcerative colitis.




































































































































ATand transcriptomic level for each gut segment. Interestingly,
IBD-derived samples displayed more variation, with a sub-
set of IBD samples distinctly separating from controls
(Figure 1Bi, Bii and Supplementary Figure 1). In contrast to
DNAm and gene transcription, no clear separation was
evident from the 16S microbial community proﬁles using
the same MDS approach (Figure 1Biii). However, analysis of
the bacterial operational taxonomic unit by family abun-
dance and alpha-diversity did reveal variation by gut
segment (Supplementary Figure 2) and reduction in species
diversity for CD patients (Supplementary Figure 2).
Taken together, initial unsupervised analysis of genome-
wide intestinal epithelial proﬁles reveals highly gut
segment-speciﬁc signatures and suggests disease-associated
alterations of DNAm and gene expression.
Disease-speciﬁc Alterations in IEC Epigenetic
and Transcriptional Proﬁles are Partly
Independent of Inﬂammation Status
Given the distinct clustering patterns we observed on a
genome-wide scale, we next used a variance component
model to assess the relative contribution of diagnosis and
inﬂammation to the observed variance within each data
layer, by gut segment. As shown in Figure 2A, the variation
explained by disease (ie, diagnosis) exceeds that of inﬂam-
mation in the majority of datasets. This highlights the
presence of disease-speciﬁc molecular alterations, which are
partly independent of the current inﬂammatory activity. Full
results of the variance decomposition analysis can be found
in Supplementary Figure 3. To extend these ﬁndings, we
performed separate differential analysis (gene expression
and DNAm) of inﬂammation and disease in the colonic
epithelium. This allowed us to identify, for each CpG site or
gene, the relative signiﬁcance of inﬂammation and disease.
Results showed that a majority of the differentiallyFLA 5.5.0 DTD  YGAST61474_proofmethylated positions (DMPs) between CD or UC and con-
trols are primarily driven by diagnostic status and not
inﬂammation (FDR <0.01, Figure 2B and C). Similarly,
diagnosis explained 74% and 82% of the differentially
expressed genes (DEGs) for CD and UC, respectively
(Figure 2D and E).
Additionally, generating MDS plots by labelling samples
according to gut segment, diagnosis, and inﬂammatory sta-
tus did not show a clear separation between inﬂamed and
non-inﬂamed samples (Supplementary Figure S1). Lastly,
we also tested for the potential impact of inﬂammation on
cellular composition in our puriﬁed samples by generating a
gene expression heat map of common epithelial and im-
mune cell marker genes (Supplementary Figure S4).
Although a number of genes were found to be differentially
expressed between IBD and control samples (eg, DEFA5,
DEFA6, LYZ, PLA2G2A, CD40, CD44), none of the marker
genes correlated with inﬂammatory status, suggesting
minimal impact of epithelial cell composition and immune
cell contamination on the observed disease-speciﬁc molec-
ular changes (Supplementary Figure S4).
In summary, these analyses demonstrate the presence of
clear epigenetic, transcriptomic, and adjacent microbial
alterations in the intestinal epithelium of children newly
diagnosed with IBD, with a proportion being independent of
intestinal inﬂammation.
Differential Methylation Analysis Reveals
Disease-speciﬁc Signatures That Affect
Gene Transcription
Next we performed differential DNAm and gene
expression analyses by comparing control, CD-, and
UC-derived datasets for each gut segment. When performing
these analyses, inﬂammation was controlled for within the
differential analysis thereby allowing us to focus on 8 January 2018  1:08 pm  ce
600
Figure 2. Contribution of
diagnosis and inﬂamma-
tion to variance within
each data layer. (A) Bar
chart of the explained
variance by diagnosis and
inﬂammation across each
dataset separated by gut
segment. (B–E) Scatterplot
of P values derived from
differential DNAm (I and I)
and gene expression (I and
I) in sigmoid colon (SC)
samples. For each CpG or
gene, P values were
generated for the compar-
ison between Crohn’s
disease (CD)/ulcerative
colitis (UC) and control,
and inﬂammation status
(ie, inﬂamed vs non-
inﬂamed). CpGs and
genes with signiﬁcant
P values are plotted in
purple for inﬂammation,
in red for diagnosis, and in
green if signiﬁcant for both
comparisons. Adjusted











































































































































ATmolecular alterations that occur in relative independence of
mucosal inﬂammation. Additionally, in an attempt to con-
nect epigenetic and transcriptomic signatures, we identiﬁed
differentially methylated regions (DMRs) that were located
within 10kb of the transcription start site of a DEG. Such
regions were termed regulatory DMRs (rDMRs).FLA 5.5.0 DTD  YGAST61474_proofAnalysis of ileal IECs revealed CD-speciﬁc changes in
both DNAm (Figure 3Ai and Supplementary Tables 5 and 6)
and gene expression (Figure 3Aii and Supplementary
Tables 7 and 8), when compared with either controls or
UC, with a proportion overlapping between the 2 compari-
sons. In contrast, no signiﬁcant DMPs or DEGs were 8 January 2018  1:08 pm  ce
720
Figure 3. Differential
DNAm and gene expres-
sion analysis were per-
formed separately for
terminal ileum (TI) (A and
B) and sigmoid colon (SC)
(C and D), taking mucosal
inﬂammation into account.










expressed as Beta value
on the y-axis in the left
panel separately for TI and
SC samples in the upper
and lower panel, respec-
tively. Beta value of 0 rep-
resents un-methylated,
while 1 represents fully
methylated CpG site.
Genomic location is indi-
cated on the x-axis. The
middle panel displays
identiﬁed rDMR (enlarged).
The right panel displays a
boxplot of the respective
gene expression accord-
ing to diagnosis. (B) rDMR
within the APOA1 identi-
ﬁed in TI-derived epithe-
lium of children diagnosed
with CD. (D) rDMR within
the BACH2 gene identiﬁed



















































































































































ATidentiﬁed when comparing UC with controls. Importantly,
amongst identiﬁed rDMRs, several have previously been
reported to be associated with IBD (eg, CASP133 and
APOA19) (Figure 3B).
Contrary to the ileum, changes observed in the SC
reﬂected a ‘common IBD’ signature, with a major overlap
between UC and CD signatures and only a single signiﬁcant
DEG (RARRES3 [Retinoic Acid Receptor Responder 3])
identiﬁed between the 2 diagnoses (Figure 3C and
Supplementary Tables 9–14). RARRES3 is thought to haveFLA 5.5.0 DTD  YGAST61474_proofgrowth inhibitory and cell differentiation activities. One
example of an rDMR that jointly affects CD and UC in the
colon is BACH2 (Figure 3D), a transcription regulator, where
a decrease in DNAm matched the increase in gene expres-
sion levels in both CD and UC patients. Interestingly, a
proportion of the CD-related changes identiﬁed in TI sam-
ples were also found to be present in SC samples
(Supplementary Figure 5).
Overall, these results indicate that CD-speciﬁc DNAm





































































































ATcontrast, molecular changes observed in the colonic
epithelium revealed a major overlap between CD and UC,
reﬂecting a ‘common IBD’ signature.
Pathway Enrichment Analysis of Identiﬁed
rDMRs Reveal Both Common IBD and
Disease-speciﬁc Pathways
The intestinal epithelium serves a wide range of functions
as a physical, chemical and immunological barrier and a
bridge between the innate and adaptive immune response.34
We used pathway enrichment analysis to investigate func-
tional pathways (of rDMRs) that may be altered at diagnosis
in a child with IBD. A wide variety of immune system-,
metabolism-, and signal transduction-related pathways were
signiﬁcantly enriched (Figure 4). Many of the immune
system-related pathways (eg, interferon signaling and
immuno-regulatory interactions) are shared between the gut
segments and diagnoses; suggesting common alterations are
present in IBD.Moreover, several of the signiﬁcantly enriched
pathways have previously been implicated in either IBD
pathogenesis or IEC function (Figure 4).FLA 5.5.0 DTD  YGAST61474_proofIBD-associated intestinal Epithelial-speciﬁc
Epigenetic Alterations are Stable Over Time and
Partly Retained in Ex-vivo Organoid Culture
Next, we investigated the stability of IEC DNAm proﬁles
in IBD patients over time. We obtained ileal and colonic
biopsies (SC) from IBD patients both at diagnosis and at a
later stage in their disease (n ¼ 14 CD, n ¼ 9 UC). Strikingly,
CD- and UC-associated DMPs showed remarkable stability
over time, demonstrated by the strong correlations of the
methylation values at diagnosis and repeat endoscopy
within each gut segment (Figure 5A and Supplementary
Figure 6). This was in spite of changes to the underlying
mucosal inﬂammatory status (see Supplementary Table 1).
To further test the stability and potential inﬂammation
independence of disease-speciﬁc epigenetic alterations in
IBD-derived IEC, we generated patient-derived intestinal
organoids from an additional cohort of children newly
diagnosed with CD (n¼5) and matched healthy controls
(n¼7). Expansion of mucosal crypts from TI and SC in
culture gave rise to 3-dimensional organoids (Figure 5B).
Organoids derived from CD patients did not differ in theirFigure 4. Pathway enrich-
ment analysis of disease-
speciﬁc regulatory DMRs
(rDMRs). Pathway enrich-
ment analysis was per-
formed on identiﬁed
rDMRs derived from the 3
comparisons between
Crohn’s disease (CD) vs
controls in terminal ileum
(TI) and sigmoid colon (SC)
samples (left and middle
panel) and ulcerative coli-
tis (UC) vs controls in SC
samples (right panel).
Analysis was performed
using InnateDB and Reac-
tome database and signif-
icant enrichment of
individual pathways is dis-
played as the -log10
(adjusted P value).















































































































































































ATmicroscopic appearance or culturing behavior from those
derived from healthy controls (Figure 5B). However,
assessing their genome-wide DNA methylation proﬁles
revealed distinct alterations, suggesting that they retain a
proportion of disease-associated epigenetic changes.
Despite the relatively small sample number, CD-associated
DMPs (ie, identiﬁed in Figure 3) showed a clear trend to
be also differentially methylated in CD-derived compared
with control organoids. This was indicated by the presence
of inﬂated P values (larger difference between observed vs
expected P values) of CD-associated DMPs compared with
randomly selected CpGs (Figure 5C). Using locus-speciﬁc
pyrosequencing, we were able to validate a subset of CD-
speciﬁc DMPs that were retained in organoid cultures
(Figure 5D and 5E).
Together, these data demonstrate that disease-
associated epigenetic alterations in the intestinal epithe-
lium are stable over time and are at least in part retained in
ex-vivo organoid cultures.
Intestinal Epithelial DMRs, DEGs, and rDMRs are
Enriched Around Genetic IBD Risk Loci
Genome-wide association studies have successfully
identiﬁed over 200 loci predisposing to IBD.4,5 However,
limited information is currently available on the potential
mechanisms involved in mediating genetic risk and/or
which cell types are particularly affected. Here we used our
epithelial cell-derived molecular signatures to test for an
enrichment of disease-speciﬁc DMRs, DEGs, and rDMRs
within genomic IBD risk loci. We observed highly signiﬁcant
enrichment of DMRs, DEGs, and rDMRs in both colonic and
ileal IECs for IBD risk loci, while limited enrichment was
found for genetic variants that have been linked to other
multifactorial diseases with an immune-mediated patho-
genesis, such as Type 1 diabetes and multiple sclerosis
(Supplementary Figure 7). Together these results suggest
that interactions between the IBD risk loci and DNAm and/
or transcription may occur in children carrying disease
variants.
IEC DNA Methylation and Gene Expression
Signatures Accurately Predict Disease Status and
Correlate With Clinical Outcome Measures
Given the striking IBD-associated changes observed in
intestinal epithelial DNAm and gene expression, we went on
to test the ability of these signatures to predict diagnosis.
Additionally, we hypothesized that variation observed
within IBD-derived patient samples could be indicative of
future disease behavior and outcome. To address these
hypotheses, we applied a machine-learning model (random
forest) to the individual omics data layers. The model
identiﬁed those data points (eg, CpGs, genes, operational
taxonomic units) that could predict disease status for each
patient with high precision and accuracy (see
Supplementary Methods section for further details). As
demonstrated in Figure 6, DNAm data derived from either
gut segment produced a model with a high AUC (>0.8)
(Figure 6A). The best model separating disease from controlFLA 5.5.0 DTD  YGAST61474_proofwas based on DNAm data from the SC (AUC¼0.94, CV Q¼40)
with sensitivity of 75% and speciﬁcity of 100% (Figure 6Ai
and 6Aii). Importantly, the use of ileal DNAm datasets
allowed separation between CD and UC with high precision
(77%), sensitivity (57%), and speciﬁcity (93%) (AUC¼0.92,
CV¼24) (Figure 6B). The accuracy of the TI DNAm signa-
tures in distinguishing CD and UC was conﬁrmed in a
follow-up patient cohort, analyzed using a second DNAm
array platform (Illumina EPIC array, see Methods and
Supplementary Figure 8). Full details of the models,
including AUC, sensitivity, and speciﬁcity, can be found in
Supplementary Table 15. In contrast, models built using the
IBD risk loci from our patient genotyping data yielded the
lowest model score (AUC¼0.49) (Figure 6Ai).
To correlate genome-wide IEC proﬁles with clinical
outcome measures (including binary, numerical, and cate-
gorical parameters) we used a WGCNA approach. WGCNA
identiﬁes patterns within a given dataset (ie, RNAseq data)
and combines genes or CpGs that vary similarly across
samples into modules. Each of these modules was then
tested for a signiﬁcant correlation with clinical outcomes.
The application of WGCNA to RNAseq data derived from the
TI of CD patients led to the identiﬁcation of several gene
modules (ie, groups of genes) that correlate signiﬁcantly
(correlation >±0 Q.6, P < .05) with a number of disease
outcome measures including the requirement for treatment
with biologics and number of treatment escalations within
the ﬁrst 18 months following diagnosis (Figure 6C). Inter-
estingly, modules correlating with disease outcome mea-
sures did not show any correlation with gender, age, or
disease phenotype at diagnosis (eg, abdominal pain, diar-
rhea, and Pediatric Crohn’s Disease Activity Index Q). Clus-
tering all samples according to expression levels of genes
within the strongest modules separated CD patients in 2
groups (Figure 6Di). Kaplan Meier curves for these groups
demonstrated striking differences in both the requirement
for biologics and time-to-third-treatment escalation
(Figure 6Dii and 6Diii). In addition, we applied WGCNA to
the DNAm data. Although the overall correlation of identi-
ﬁed modules was less striking, separating samples accord-
ing to DNAm proﬁles of the strongest module still
demonstrated a signiﬁcant difference in outcome measures
between resulting patient groups (Figure 6Ei–6Eiii). Similar
results were obtained from UC patient-derived signatures in
SC samples (Supplementary Figure 9). Finally, comparing
annotated genes from the top modules identiﬁed in RNAseq
and DNAm datasets revealed an overlap of 57% and 79%,
respectively, suggesting that expression signatures might be
in part underpinned by stable epigenetic changes
(Figure 6F). Based on these preliminary results, both DNAm
and RNAseq data contain signatures that accurately predict
disease status and correlate with selected disease outcome
parameters.Discussion
Substantial evidence suggests that impaired function of
the intestinal epithelium plays a major role in IBD patho-




















































































ATmechanisms remains limited. It is also becoming increas-
ingly clear that functional alterations in complex disease are
likely to be caused by and/or result in a multifaceted
interplay between several layers of cellular regulation.FLA 5.5.0 DTD  YGAST61474_proofSpeciﬁc to the GI tract, the intestinal microbiota adds further
complexity because it has been shown to inﬂuence cellular
function of the intestinal epithelium both in health and






























































































































































































ATspectrum of disease behavior within the conditions we
currently label as CD and UC, we urgently require novel
molecular signatures to allow better classiﬁcation of clini-
cally relevant disease entities.
Here, we applied a multi-omics proﬁling approach to a
highly puriﬁed IEC sample set obtained from a prospectively
recruited, treatment-naïve, pediatric patient cohort. Unsu-
pervised analysis revealed fundamental differences in the
methylation and gene expression proﬁles by gut
segment.9,10,16 Moreover, within each gut segment, we
observed distinct disease-speciﬁc variation in both DNAm
and gene expression, which were found to be partly inde-
pendent of the presence or absence of microscopic mucosal
inﬂammation. Speciﬁcally, we found that the majority of
DNAm and RNAseq disease signatures from the SC were not
primarily explained by inﬂammation status. This strongly
suggests that there are underlying epigenetic and tran-
scriptomic changes within IECs in IBD patients, which are
present irrespective of inﬂammatory activity. Our ﬁndings
further expand on previous studies using whole gut bi-
opsies, which reported major transcriptional or epigenetic
changes that were primarily associated with the presence of
mucosal inﬂammation.9,10 Although we also observed a
strong, inﬂammation-associated signal, puriﬁcation of the
intestinal epithelium (and thereby removal of inﬁltrating
immune cells) has allowed identiﬁcation of a cell type-
speciﬁc signature that does not seem to be exclusively
driven by mucosal inﬂammation.
In contrast to genome-wide DNAmand gene transcription
proﬁles, unsupervised MDS analysis of our 16S data did not
show any speciﬁc sample clusters and/or clear association
with key phenotypes such as gut segment, disease entity, or
inﬂammation. This is most likely because of the large inter-
individual and intra-individual variation; an observation
that has been previously reported by others.9,11,12 However,
supervised analyses revealed gut segment as well as disease-
associated changes in microbial composition. Analysis of the
16S data in combination with the epithelial omics data was
unable to identify strong correlations between DEGs and 16S
abundances or dose-dependent relationships for subgroups
of patients. Nevertheless, we consider the fact that our 16S
data was generated from microbes isolated from individual
gut segments as novel and therefore potentially highly valu-
able as reference for futurework in this rapidly evolving ﬁeld.
Further investigating disease-speciﬁc DNAm and gene
expression changes, we were able to identify a number of=
Figure 5. Stability of disease-associated intestinal epithelial DNA
(Beta values) of disease-associated differentially methylated pos
patient at the 2 time points. Shown are Crohn’s disease (CD)-
DMPs (right) in sigmoid colon (SC) epithelium (adjusted P <. 01
epithelial organoids derived from 2 gut segments (ie, terminal
quantile plot generated from organoid-derived genome-wide D
comparing speciﬁc CD-associated DMPs (from Figure 3) for eac
CD-associated DMPs being retained in patient-derived organo
data generated from puriﬁed colonic epithelium and respective
Cancer 1; TMEM173, Transmembrane Protein 173; PDE1B, Pho
CD puriﬁed IEC (n ¼ 13); CtrlO, Control organoids (n ¼ 7); CD
Validation of genome-wide DNAm data using pyrosequencing. n
test between Ctrl and CD.
FLA 5.5.0 DTD  YGAST61474_proofsigniﬁcant DEGs and DMRs, a proportion of which over-
lapped (rDMRs), indicating a functional interconnection
between the 2 data layers. Reassuringly, a number of
identiﬁed genes had previously been reported, including
APOA112 and CASP1.9 When comparing identiﬁed DMRs,
DEGs, and rDMRs, we discovered that signiﬁcant changes in
the TI were only present in CD-derived samples. In contrast,
analysis in the colonic epithelium showed both CD- and
UC-speciﬁc changes, which also displayed a major overlap
likely reﬂecting common phenotypic features shared be-
tween the 2 conditions. Together these data suggest the
presence of a CD-speciﬁc signature in the TI epithelium and
a common IBD signature in the SC. The identiﬁcation of
shared, enriched pathways for the 2 diagnoses further
supports this hypothesis. Additionally, enrichment for
pathways implicated in the cross-talk between cells of the
innate and adaptive immune response highlights the
important role of the intestinal epithelium in orchestrating
intestinal host defense and suggests that alterations in these
key processes may lead to the initiation and/or persistence
of gut inﬂammation in IBD.
The impact of the observed IEC-speciﬁc epigenetic al-
terations on IBD pathogenesis will depend at least in part on
the stability of such molecular signatures. Investigating IEC
DNAm proﬁles of the same patient at 2 time points (ie, at
diagnosis and at later disease stage) allowed us to demon-
strate the strikingly high stability of disease-associated
methylation signatures in small bowel and colonic IEC.
This was despite changes in medication and mucosal
inﬂammation over a period of up to 20 months. These
ﬁndings suggest that stable epigenetic alterations may
contribute to chronic relapsing inﬂammation by mediating
altered IEC function. Interestingly, CD-derived epithelium
appeared to retain a degree of disease-speciﬁc alterations
even when cultured ex-vivo as organoids, further high-
lighting both their stability and relative independence of
mucosal inﬂammation. Additionally, our ﬁndings add
further support to recent reports on patient-derived intes-
tinal organoids to be used as novel translational research
tools.35
Despite the major success of genome-wide association
studies in identifying disease-predisposing genetic loci,
information on the functional consequences and cell speci-
ﬁcity remain limited. Expression quantitative trait loci have
been identiﬁed for a subset of the IBD risk loci from whole
biopsies36 and blood cell subsets.37 More recently,methylation changes: (A) Correlation plot of DNA methylation
itions (DMPs) at diagnosis and at repeat endoscopy for each
associated DMPs (left) and ulcerative colitis (UC)-associated
). (B) Brightﬁeld microscopic images of fully grown intestinal
ileum [TI] and SC) of CD and control patients. (C) Quantile-
NAm P values. Plotted are P values (observed vs expected)
h gut segment with randomly selected CpGs. (D) Examples of
ids. Plotted are beta values derived from genome-wide array
organoids. GREB1, Growth Regulation By Estrogen In Breast
sphodiesterase 1B; CtrlP, Control puriﬁed IEC (n ¼ 14); CDP,
O, CD organoids (n ¼ 5). (E) Validation of CpGs shown in D.
¼ 5–7 per group; *P < .05; ***P < .001; unpaired, 2-tailed t-















Figure 6. Correlation of intestinal epithelial cells (IEC)-speciﬁc molecular signatures with diagnosis and clinical outcome
measures: IEC-derived epigenetic, transcriptomic, and microbial signatures were tested for their potential to predict diagnostic
status (A and B) and correlation with disease outcome parameters (C–F). (Ai) Bar chart indicating area under the curve (AUC) of
the best model to accurately differentiate samples based on diagnosis (ie, IBD vs controls). (Aii) ROC curve for the best
diagnostic model (inﬂammatory bowel disease [IBD] vs control) using colonic DNAm data. (Bi) Bar chart of the AUC of the best
models to differentiate between Crohn’s disease (CD) and ulcerative colitis (UC). (Bii) Receiver operator characteristic (ROC)
curve for the best model separating CD from UC using ileal IEC DNAm data. (C) Weighted Gene Co-Expression Network
Analysis (WGCNA) of CD terminal ileum (TI)-derived RNA-Seq data showing correlations between key gene-expression
modules and clinical parameters. Each cell on the heatmap displays Pearson correlation coefﬁcient and corresponding
P value. Outlined cells indicate signiﬁcant correlations. (D) Heatmap and hierarchical clustering of patients based on gene
expression (ie, RNAseq counts) for strongest module. (Dii and Diii) Kaplan-Meier curves based on patient grouping derived
from 7Di, ie, top gene expression module for use of biologics and time to third treatment escalation during 75 weeks of follow-
up (n ¼ 10 patients, P ¼ .049 and P ¼ .032, log-rank test). (Ei) Heat-map and hierarchical clustering of CpGs within strongest
module identiﬁed by applying WCGNA to CD TI DNA methylation proﬁles. (Eii and Eiii) Kaplan Meier curves based on patient
grouping derived from 7Ei for use of biologics (Eii) and time to third treatment escalation (Eiii) during 75 weeks follow-up
(n ¼ 29 patients, P ¼ .025 and P ¼ .043, log-rank test). (F) Venn-diagram showing the overlap between annotated genes
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ATdifferences in DNAm and chromatin conformation38 were
also identiﬁed for a subset of the IBD risk loci in immune
cells.39 Our study adds further detail and speciﬁcity by
demonstrating enrichment of disease-speciﬁc DMRs, DEGs,
and rDMRS within IBD susceptibility loci4,5 in both gut
segments.
An additional major strength of our prospectively
recruited pediatric patient cohort was the availability of
detailed phenotype and disease outcome data, allowing us
to test for potential correlation between molecular signa-
tures and clinical phenotypes. Despite the relatively small
sample numbers included in these analyses, both the
potential diagnostic and prognostic value of our IEC signa-
tures is evident. While current diagnostic approaches are
sufﬁcient for most patients, a minority of patients require
repeated and prolonged investigations to conﬁrm a diag-
nosis. Additionally, it is frequently challenging to differen-
tiate UC from CD in children, both at diagnosis and later in
the disease course. Therefore, a diagnostic model to reliably
differentiate CD from UC, such as the model built using
DNAm data from the ileum with high sensitivity and speci-
ﬁcity, could be of clinical value. Correlating genome-wide
molecular signatures with clinical outcome measures
continue to be a major challenge and a wide range of bio-
informatics tools have been developed. We decided to utilize
WGCNA, which has been successfully applied to both RNA-
seq and DNAm datasets, allowing identiﬁcation and corre-
lation of individual gene modules with clinical parameters.40
Results are highly encouraging because we discovered a
number of gene expression modules that correlated strongly
with the number of relapses and the requirement for
treatment with biologics. Interestingly, overlapping modules
derived from applying WGCNA to RNAseq data with those
derived from DNAm data revealed a major overlap, sug-
gesting prognostic expression signatures maybe at least in
part underpinned by epigenetic changes.
As a limitation to our study, we acknowledge that the
total number of patients included is relatively low and
hence some of the analyses performed, particularly those
that correlate signatures with clinical outcome, should be
considered as preliminary. However, to the best of our
knowledge this is the ﬁrst and largest study applying a
multi-omics proﬁling approach to a unique sample collec-
tion of highly puriﬁed intestinal epithelium. The fact that all
patients were recruited at diagnosis (treatment-naïve) also
represents an important strength. Last but not least,
although our study was performed on a pediatric patient
cohort, we consider our ﬁndings to be equally relevant to
adult-onset IBD given the similarities in disease phenotype
(particularly in teenage onset) and common concepts of
disease pathogenesis.
In summary, our study is the ﬁrst to apply a multi-omics
proﬁling approach to a large collection of puriﬁed intestinal
epithelial samples. The ﬁndings clearly demonstrate
disease-speciﬁc abnormalities in epithelial cell function in
children with IBD. We also highlight how speciﬁc data sig-
natures might be indicative of disease status and behavior
and therefore have a potential to be of clinical relevance in
the future.FLA 5.5.0 DTD  YGAST61474_proofSupplementary Material
Note: To access the supplementary Qmaterial accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at https://doi.org/10.1053/
j.gastro.2017.10.007. 8References
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